Tracking emotional and behavioral issues in youth born to women with HIV
Among youth born to women with HIV, those who were born without HIV had worse behavioral functioning than those born with HIV, a new study found.
Among expectant mothers, HIV medication efavirenz carries risks
Efavirenz, a drug used in the treatment of HIV, may increase the risk of microcephaly among children whose mothers take the medication during pregnancy, according to new research led by Harvard T.H. Chan School researchers and supported by…
HIV antiretrovirals have varying cardiac effects on infected children
Early in the HIV/AIDS epidemic, children born with the virus often suffered from severe cardiac-related conditions. These conditions have largely been alleviated by current antiretroviral treatment combinations, but some risks remain.
Margaret Kruk, Donna Spiegelman, Paige Williams honored at annual Alice Hamilton Award lecture
Margaret Kruk was honored for her work on improving health care quality around the world at the eighth annual Alice Hamilton Award lecture on May 8, 2018, at Harvard T.H. Chan School of Public Health.
Risks to babies of mothers with HIV from three antiretroviral regimens appear to be low
For immediate release: April 25, 2018 Boston, MA – The risk for preterm birth and early infant death is similar for three antiretroviral drug regimens taken by pregnant women with HIV, according to a new study from Harvard…
Monitoring the safety of ARV therapy during pregnancy
December 1, 2015 — Paige Williams, senior lecturer on biostatistics at Harvard T.H. Chan School of Public Health, studies the health and development of children whose HIV-infected mothers took antiretroviral (ARV) drugs during pregnancy. In a study published…
Overall risk of birth defects appears low for women taking antiretrovirals during early pregnancy
For immediate release: Monday, November 10, 2014 Boston, MA – Among pregnant women infected with HIV, the use of antiretroviral (ARV) medications early in pregnancy to treat their HIV or to prevent mother-to-child transmission of HIV does not…
HIV-infected children may be protected against puberty delays by newer drugs
October 15, 2013 — In a new study, researchers from Harvard School of Public Health (HSPH) found that newer combination antiretroviral (ARV) drug therapies for HIV appear to protect against puberty delays among children born with HIV. “We…
HSPH research pinpoints strategy for monitoring antiretrovirals' effects on children of HIV-infected mothers
July 30, 2012 -- Harvard School of Public Health (HSPH) researchers have found an effective and cost-efficient strategy for monitoring the health and development of children whose HIV-infected mothers took antiretroviral (ARV) drugs during pregnancy, and for estimating the…
